| Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer NCT03937154 | Fase 3 | En marcha, sin reclutar |
| ROMISTER NCT07700238 | Fase 3 | Reclutando pacientes |
| Efficacy of Romiplostim in Treatment of SAA in Adults Previously Untreated With or Refractory to Immunosuppressive Therapy NCT05323617 | Fase 2 | Retirado antes de empezar |
| RECITE NCT03362177 | Fase 3 | Completado |
| Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Lymphoma. NCT03343847 | Fase 3 | Retirado antes de empezar |
| Long-term Study of Romiplostim in Thrombocytopenic Pediatric Patients With Immune Thrombocytopenia (ITP) NCT02279173 | Fase 3 | Completado |
| A Study Evaluating the Safety and Efficacy of Long-term Dosing of Romiplostim in Thrombocytopenic Pediatric Patients With Immune (Idiopathic) Thrombocytopenia Purpura NCT01071954 | Fase 3 | Completado |
| Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients NCT01444417 | Fase 3 | Completado |
| Study on Bone Marrow Morphology in Adults Receiving Romiplostim for Treatment of Thrombocytopenia Associated With Immune Thrombocytopenia Purpura (ITP) NCT00907478 | Fase 4 | Completado |
| Interventional Study in Adults With Immune Thrombocytopenia Purpura (ITP) Receiving Romiplostim NCT01143038 | Fase 2 | Completado |
| Síndromes mielodisplásicos NCT00472290 | Sin fase asignada | Completado |
| Síndromes mielodisplásicos NCT00614523 | Fase 2 | Completado |
| An Open Label Study of Romiplostim in Adult Thrombocytopenic Subjects With ITP NCT00508820 | Fase 3 | Completado |
| Open Label Extension Study of Romiplostim (AMG 531) in Thrombocytopenic Patients With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) NCT00116688 | Fase 3 | Completado |
| Cáncer de pulmón, Cáncer de pulmón no microcítico NCT00413283 | Fase 2 | Completado |
| Síndromes mielodisplásicos NCT00303472 | Fase 2 | Completado |
| Amgen Megakaryopoiesis Protein 2 (AMG 531) in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP) NCT00117143 | Fase 1/2 | Completado |
| Evaluating the Safety and Efficacy of Romiplostim (AMG 531) in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP) NCT00111475 | Fase 2 | Completado |